Johnson & Johnson’s one-shot COVID-19 vaccine appears to provide more protection against worrisome virus variants than the drug giant initially reported, according to new trial data released in advance of a Friday advisory panel meeting on whether to recommend the vaccine as the third cleared for emergency use in the US.
Company briefing documents posted on the Food and Drug Administration website Wednesday indicate the vaccine was 68 percent effective at preventing moderate to severe disease caused by the dominant variant in Brazil and 64 percent effective against the dominant variant in South Africa.
Read the full story on BostonGlobe.com.
Related: COVID-19 vaccine news, resources, and guidance
|
|
|
|
|
We have lots of e-mail newsletters on a variety of topics, including news, politics, business, sports, lifestyle, and more. They're free, and it's easy to subscribe. Here's a complete list.
|
|
|
|
